AlphaCrest Capital Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

AlphaCrest Capital Management’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-5,400	Closed	-$552K	–	1238
2020 Q2	$552K	Buy	+5,400	New	+$578K	0.09%	349
2020 Q1	–	Sell	-4,800	Closed	-$559K	–	1380
2019 Q4	$559K	Sell	4,800 -8,600	-64%	-$996K	0.05%	718
2019 Q3	$1.53M	Buy	+13,400	New	+$1.33M	0.09%	346

Other funds holding CBPO

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MCP

Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capstone Investment Advisors New York $57.4B AUM 26.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

AlphaCrest Capital Management's CBPO Position: Q3 2020 in Review

AlphaCrest Capital Management sold out of China Biologic Products Holdings, Inc. (CBPO) in Q3 2020, closing a stake of 5,400 shares — an estimated $552K sold.

AlphaCrest Capital Management first reported a position in CBPO in Q3 2019 and held it in 3 quarters. The position peaked at $1.53M in Q3 2019. 87 funds tracked by Wall St. Rank hold CBPO as of Q3 2020.

AlphaCrest Capital Management reported no remaining China Biologic Products Holdings, Inc. position as of Q3 2020 after selling out during the quarter.
AlphaCrest Capital Management sold 5,400 China Biologic Products Holdings, Inc. shares in Q3 2020, an estimated $552K.
AlphaCrest Capital Management first reported a position in China Biologic Products Holdings, Inc. in Q3 2019 and held it in 3 quarters.
AlphaCrest Capital Management's China Biologic Products Holdings, Inc. position peaked at $1.53M in Q3 2019.
87 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q3 2020.

Based on AlphaCrest Capital Management's 13F filing for Q3 2020, filed 12 Nov 2020.